Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?

Background: Lipin-1 deficiency is a life-threatening disease that causes severe rhabdomyolysis (RM) and chronic symptoms associated with oxidative stress. In the absence of treatment, Hydroxychloroquine sulfate (HCQ) was administered to patients off label use on a compassionate basis in order to improve their physical conditions.Methods: Eleven patients with LPIN1 mutations were treated with HCQ. Clinical and biological efficacy and tolerance were assessed, including pain and quality of life, physical capacities, cardiopulmonary parameters, creatine kinase levels and plasma proinflammatory cytokines. To explore a dose-dependent effect of HCQ, pri-mary myoblasts from 4 patients were incubated with various HCQ concentrations in growth medium (GM) or during starvation (EBSS medium) to investigate autophagy and oxidative stress.Findings: Under HCQ treatment, patient physical capacities improved. Abnormal cardiac function and peripheral muscle adaptation to exercise were normalized. However, two patients who had the highest mean blood HCQ concentrations experienced RM. We hypothesized that HCQ exerts deleterious effects at high concentrations by blocking autophagy, and beneficial effects on oxidative stress at low concentrations. We confirmed in primary myoblasts from 4 patients that high in vitro HCQ concentration (10 mu M) but not low concentration (1 mu M and 0.1 mu M) induced autophagy blockage by modifying endolysosomal pH. Low HCQ concentration (1 mu M) prevented reactive oxygen species (ROS) and oxidized DNA accumulation in myoblasts during starvation.

Automated summary

This study tested the effect of hydroxychloroquine sulfate treatment in Lipin-1 deficient patients. It was found that the physical conditions of the patients improved, but there was a risk of rhabdomyolysis at high concentrations. The study also found that hydroxychloroquine sulfate can reduce oxidative stress at low concentrations.